Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients

Lenalidomide in combination with dexamethasone (Len‐dex) represents a highly effective treatment in relapsed/refractory multiple myeloma (RRMM) patients. However, an increased risk of secondary primary malignancies (SPMs), including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotchetkov, Rouslan, Masih‐Khan, Esther, Chu, Chia‐Min, Atenafu, Eshetu G., Chen, Christine, Kukreti, Vishal, Trudel, Suzanne, Tiedemann, Rodger, Reece, Donna E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269689/
https://www.ncbi.nlm.nih.gov/pubmed/27860411
http://dx.doi.org/10.1002/cam4.799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5269689/
https://www.ncbi.nlm.nih.gov/pubmed/27860411
http://dx.doi.org/10.1002/cam4.799

Ejemplares similares